IP Verse

Pharmaceutical Composition Comprising Crystalline (2S,3R,4S,5S,6R)-2-[4-Chloro-3-(4-Ethoxy-Benzyl)-Phenyl]-6-Hydroxymethyl-2-Methoxy-Tetrahydro-Pyran-3,4,5-Triol (S)-Propylene Glycol Solvate - EP3363807

The patent EP3363807 was granted to Astrazeneca on Nov 13, 2019. The application was originally filed on Jun 21, 2007 under application number EP17203302A. The patent is currently recorded with a legal status of "Granted And Under Opposition".

EP3363807

ASTRAZENECA
Application Number
EP17203302A
Filing Date
Jun 21, 2007
Status
Granted And Under Opposition
Oct 11, 2019
Publication Date
Nov 13, 2019
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

GENERICS UKAug 13, 2020TER MEER STEINMEISTER & PARTNER -

Patent Citations (82) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication Number
DESCRIPTIONUS19990391053
DESCRIPTIONUS20000519079
DESCRIPTIONUS20030745075
DESCRIPTIONUS20040899641
DESCRIPTIONEP0142146
DESCRIPTIONEP0221025
DESCRIPTIONFR2596393
DESCRIPTIONGB2205837
DESCRIPTIONUS3674836
DESCRIPTIONUS3983140
DESCRIPTIONUS4027009
DESCRIPTIONUS4231938
DESCRIPTIONUS4346227
DESCRIPTIONUS4448784
DESCRIPTIONUS4450171
DESCRIPTIONUS4499289
DESCRIPTIONUS4613610
DESCRIPTIONUS4647576
DESCRIPTIONUS4681893
DESCRIPTIONUS4686237
DESCRIPTIONUS4759923
DESCRIPTIONUS4871721
DESCRIPTIONUS4924024
DESCRIPTIONUS5006530
DESCRIPTIONUS5011930
DESCRIPTIONUS5177080
DESCRIPTIONUS5260440
DESCRIPTIONUS5273995
DESCRIPTIONUS5354772
DESCRIPTIONUS5385929
DESCRIPTIONUS5488064
DESCRIPTIONUS5491134
DESCRIPTIONUS5506219
DESCRIPTIONUS5515117
DESCRIPTIONUS5541204
DESCRIPTIONUS5594016
DESCRIPTIONUS5595872
DESCRIPTIONUS5612359
DESCRIPTIONUS5614492
DESCRIPTIONUS5686104
DESCRIPTIONUS5691322
DESCRIPTIONUS5712279
DESCRIPTIONUS5712396
DESCRIPTIONUS5739135
DESCRIPTIONUS5753675
DESCRIPTIONUS5760246
DESCRIPTIONUS5770615
DESCRIPTIONUS5776983
DESCRIPTIONUS5827875
DESCRIPTIONUS5885983
DESCRIPTIONUS5962440
DESCRIPTIONUS6043265
DESCRIPTIONUS6395767
DESCRIPTIONUS6414126
DESCRIPTIONUS6515117
DESCRIPTIONUS6653314
DESCRIPTIONUS7164015
DESCRIPTIONWO0001389
DESCRIPTIONWO0039077
DESCRIPTIONWO0121602
DESCRIPTIONWO0168603
DESCRIPTIONWO03033671
DESCRIPTIONWO8603488
DESCRIPTIONWO8607054
DESCRIPTIONWO9638144
DESCRIPTIONWO9712613
DESCRIPTIONWO9712615
DESCRIPTIONWO9721993
DESCRIPTIONWO9900353
DESCRIPTIONWO9938501
DESCRIPTIONWO9946272
DESCRIPTIONWO9961431
DESCRIPTIONWO9967278
DESCRIPTIONWO9967279
OPPOSITIONUS2002111315
OPPOSITIONUS2003114390
OPPOSITIONUS2016347731
OPPOSITIONWO02083066
OPPOSITIONWO03099836
OPPOSITIONWO2004060347
OPPOSITIONWO2004063209
SEARCHWO2004063209

Non-Patent Literature (NPL) Citations (33) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference Text
DESCRIPTION- "ACAT inhibitors: physiologic mechanisms for hypolipidemic and anti-atherosclerotic activities in experimental animals", KRAUSE et al., Inflammation: Mediators Pathways, CRC, (19950000), pages 173 - 98
DESCRIPTION- A.E. BENNETT et al., J. Chem. Phys., (19950000), vol. 103, page 6951
DESCRIPTION- ASHWORTH et al., Bioorg. & Med. Chem. Lett., (19960000), vol. 6, no. 22, pages 1163 - 1166,2745-2748
DESCRIPTION- Atherosclerosis, (19950000), vol. 115, pages 45 - 63
DESCRIPTION- BILLER et al., J. Med. Chem., (19880000), vol. 31, no. 10, pages 1869 - 1871
DESCRIPTION- BILLER, S.A.; NEUENSCHWANDER, K.; PONPIPOM, M.M.; POULTER, C.D., Current Pharmaceutical Design, (19960000), vol. 2, pages 1 - 40
DESCRIPTION- CAPSON, T.L., "PhD dissertation", Dept. Med. Chem. U of Utah, Abstract, Table of Contents, (19870600), pages 16,17,40 - 43,48-51
DESCRIPTION- COREY; VOLANTE, J. Am. Chem. Soc., (19760000), vol. 98, pages 1291 - 1293
DESCRIPTION- CORNICELLI et al., "15-Lipoxygenase and its Inhibition: A Novel Therapeutic Target for Vascular Disease", Current Pharmaceutical Design, (19990000), vol. 5, pages 11 - 20
DESCRIPTION- Drugs of the Future, (19990000), vol. 24, pages 425 - 430
DESCRIPTION- Drugs of the Future, (19990000), vol. 24, pages 9 - 15
DESCRIPTION- GHISELLI; GIANCARLO, "The pharmacological profile of FCE 27677: a novel ACAT inhibitor with potent hypolipidemic activity mediated by selective suppression of the hepatic secretion of ApoBlOO-containing lipoprotein", Cardiovasc. Drug Rev., (19980000), vol. 16, no. 1, pages 16 - 30
DESCRIPTION- G. METZ; X. WU; S.O. SMITH, J. Magn. Reson. A, (19940000), vol. 110, pages 219 - 227
DESCRIPTION- HUGHES et al., Biochemistry, (19990000), vol. 38, no. 36, pages 11597 - 11603
DESCRIPTION- J. Med. Chem., (19980000), vol. 41, page 973
DESCRIPTION- JOHANNSSON, J. Clin. Endocrinol. Metab., (19970000), vol. 82, pages 727 - 734
DESCRIPTION- J.W. MULLIN; J. NYVLT, "Programmed cooling of batch crystallizers", Chemical Engineering Science, (19710000), vol. 26, pages 369 - 377
DESCRIPTION- MCCLARD, R.W. et al., J.A.C.S., (19870000), vol. 109, page 5544
DESCRIPTION- MURAKAMI et al., "A Novel Insulin Sensitizer Acts As a Coligand for Peroxisome Proliferation - Activated Receptor Alpha (PPAR alpha) and PPAR gamma. Effect on PPAR alpha Activation on Abnormal Lipid Metabolism in Liver of Zucker Fatty Rats", Diabetes, (19980000), vol. 47, pages 1841 - 1847
DESCRIPTION- "Polymorphism in Pharmaceutical Solids", Theory and Origin of Polymorphism, (19990000), ISBN 8247-0237
DESCRIPTION- P. ORTIZ DE MONTELLANO et al., J. Med. Chem., (19770000), vol. 20, pages 243 - 249
DESCRIPTION- SLISKOVIC et al., "ACAT inhibitors: potential anti-atherosclerotic agents", Curr. Med. Chem., (19940000), vol. 1, no. 3, pages 204 - 225
DESCRIPTION- STOUT et al., Chemtracts: Org. Chem., (19950000), vol. 8, no. 6, pages 359 - 362
DESCRIPTION- W.L. EARL; D.L. VANDERHART, J. Magn. Reson., (19820000), vol. 48, pages 35 - 54
DESCRIPTION- YAMADA et al., Bioorg. & Med. Chem. Lett., (19980000), vol. 8, pages 1537 - 1540
DESCRIPTION- YIN. S.; SCARINGE, R.P.; DIMARCO, J.; GALELLA, M.; GOUGOUTAS, J.Z., American Pharmaceutical Review, (20030000), vol. 6, no. 2, page 80
DESCRIPTION- SMITH, C. et al., "RP 73163: a bioavailable alkylsulfinyl-diphenylimidazole ACAT inhibitor", Bioorg. Med. Chem. Lett., (19960000), vol. 6, no. 1, doi:doi:10.1016/0960-894X(95)00555-8, pages 47 - 50, XP004135121
DESCRIPTION- NICOLOSI et al., "The ACAT inhibitor, Cl-1011 is effective in the prevention and regression of aortic fatty streak area in hamsters", Atherosclerosis (Shannon, Irel)., (19980000), vol. 137, no. 1, doi:doi:10.1016/S0021-9150(97)00279-7, pages 77 - 85, XP000997273
DESCRIPTION- SENDOBRY et al., "Attenuation of diet-induced atherosclerosis in rabbits with a highly selective 15-lipoxygenase inhibitor lacking significant antioxidant properties", Brit. J. Pharmacology, (19970000), vol. 120, doi:doi:10.1038/sj.bjp.0701007, pages 1199 - 1206, XP002372703
OPPOSITION- Anonymous, "European Medicines Agency ICH Topic Q 6 A Specifications: Test Procedures and Acceptance Criteria for New Drug Substances and New Drug Products: Chemical Substances Step 5 NOTE FOR GUIDANCE SPECIFICATIONS: TEST PROCEDURES AND ACCEPTANCE CRITERIA FOR NEW DRUG SUBSTANCES AND NEW DRUG PRODUCTS: CHEMICAL SUBSTANCES", (20060101), pages 1 - 32, URL: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500002823.pdf, (20150904), XP055211303
OPPOSITION- Banker Gilbert S, Rhodes Christopher T., "Modern Pharmaceutics. Fourth Ed. Excerpt", Marcel Dekker, Inc, (20020101), pages cover, 172 - 174, XP055822414
OPPOSITION- Henck Jan-Olav, Grieser J., Burger Arthur, "Polymorphie von Arzneistoffen. Eine wirtschaftliche Herausforderung?", Phar. Ind., (19970101), vol. 59, pages 165 - 169, XP055822418
OPPOSITION- HANDLON A L, "Sodium glucose co-transporter 2 (SGLT2) inhibitors as potential antidiabetic agents", EXPERT OPINION ON THERAPEUTIC PATENTS, GB, (20050101), vol. 15, no. 11, doi:10.1517/13543776.15.11.1531, ISSN 1354-3776, pages 1531 - 1540, XP002388315

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents